Expert Insights into Emerging Oral Psoriasis Treatments

EP: 1.Frontline Forum Sneak Peek: Expert Insights on Psoriasis Treatment Guidelines

Now Viewing

EP: 2.Expert Insights into Emerging Oral Psoriasis Treatments

EP: 3.Navigating TYK-2 Inhibitor Use for Psoriasis Maintenance and Long-Term Benefits

EP: 4.Expert Insights into Emerging Topical Psoriasis Treatments

EP: 5.Expert Insights into Emerging Biologic Psoriasis Treatments

EP: 6.Safety Considerations in Emerging Biologic Treatments for Plaque Psoriasis

EP: 7.Frontline Forum Part 1: Challenges and Opportunities to Enhance Psoriasis Management

EP: 8.Frontline Forum Part 2: Challenges and Opportunities to Enhance Psoriasis Management

EP: 9.Frontline Forum Part 3: Challenges and Opportunities to Enhance Psoriasis Management

EP: 10.Discovering Dermatology Times: March 2024 Enhancing Psoriasis Management Supplement

Panelists:

Linda Stein-Gold, MD

Henry Ford Health

Detroit, Michigan

Mona Shahriari, MD

Yale University

New Haven, Connecticut

Micheal Cameron, MD, FAAD

Cameron Dermatology

New York, New York

Leon Kircik, MD

DermResearch, PLLC

Louisville, Kentucky

George Han, MD

Hofstra University

Long Island, New York

Program Description:

Experts in the management of skin conditions discuss the latest developments in plaque psoriasis management, covering emerging oral therapies, novel topical treatments, and advancements in biologic therapy. The discussion provides practical insights for healthcare professionals to integrate these innovations into daily clinical practice for optimal patient outcomes. Additionally, the panel addresses the strategic placement of emerging therapies within current treatment guidelines, ensuring participants stay informed about the evolving landscape of psoriasis care.

Segment Description:

Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.